ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Teva Pharmaceutical Industries has renewed its support of the Teva Pharmaceutical Scholars program administered by the ACS Office of Research Grants.
The program provides three-year grants of $100,000 per year to recently tenured faculty members of Ph.D.-granting institutions in the U.S. The grants provide support for research in organic chemistry with potential or direct connection with medicinal or pharmaceutical chemistry. Additionally, the supported research is expected to be of potential practical benefit to the discovery of organic compounds useful in human medicine.
“The ACS Office of Research Grants is both very pleased and grateful that Teva has renewed their commitment to the Teva Pharmaceutical Scholars program,” says Nancy J. Jensen, who is ACS’s program manager for Teva Pharmaceutical Scholars.
The 2015 Teva Scholars will be announced at the fall ACS national meeting in Boston, where the 2012 Teva Scholars, Phil Baran, John Lavigne, and Ming Xian, will present their research.
Announcements of ACS news may be sent to acsnews.cen@acs.org
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter